Small molecule-based Lifespan extension therapy: E6AP extends mammalian life span via up regulation of its target gene BubR1, 21/May/2015, 22.49

Growth hormone therapy: p63 increases the expression of Growth hormone (GH) via down regulation of its target gene, 21/May/2015, 22.46
May 21, 2015
Small RNA-based therapy for pulmonary arterial hypertension: miR-let-7f-1 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 21/May/2015, 23.09
May 21, 2015
Show all

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published in the 1 July  2014 issue of the journal  “EMBO” by Prof David Andrew Sinclair, North BJ, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small moleculebased Lifespan extension therapy: E6AP extends mammalian life span via up regulation of its target gene BubR1. Thus, pharmacological formulations encompassing “E6AP activators or small molecule compounds that increase both E6AP and BubR1 may be used to extend the lifespan of an individual. 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How E6AP  increases the expression of BubR1

To citeBoominathan, Small molecule-based Lifespan extension therapy: E6AP extends mammalian life span via up regulation of its target gene BubR1, 21/May/2015, 22.49,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.